Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jonathan Rothberg, Ronald Lindsay, Ardy Arianpour, John Luckey


Jonathan Rothberg has resigned from his position as CEO of Life Technologies' Ion Torrent business, according to a filing with the US Securities and Exchange Commission. Ronnie Andrews, Life Tech's president of genetic and medical sciences, will oversee the Ion Torrent business in addition to continuing in his current role.

Sequenom's executive vice president of strategic planning Ronald Lindsay is cutting back to part-time hours, the company said in a US Securities and Exchange Commission filing this week. Lindsay will reduce his time commitment by half and will receive a pro-rated portion of his $358,000 salary. Lindsay also currently serves on the company's board of directors.

Ardy Arianpour is now senior vice president of business development at Ambry Genetics. Previously he was vice president of business development at the company. Prior to joining Ambry in 2009, he held several positions at Cogenics. He holds an MBA from the Marshall Goldsmith School of Management at Alliant International University/University of California, San Diego and a BS from the University of California, Irvine.

PathoGenetix has appointed John Luckey to be vice president of engineering. In the role, he will lead development and integration for the firm's Resolution Microbial Genotyping System.

Luckey previously was technical projects director with Roche NimbleGen, and he managed software development and instrumentation engineering activities at OpGen Technologies. He also founded GeneSys Technologies to market the BaseStation DNA Fragment Analyzer, which he designed and developed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.